Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Urokinase Market Outlook, In‑Depth Analysis & Forecast to 2031

Global Urokinase Market Outlook, In‑Depth Analysis & Forecast to 2031

Industry: Pharma & Healthcare

Published Date: 2025-09-11

Pages: 147 Pages

Report ld: 5043894

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Industry Insights:

Urokinase Research：CAGR of 4.7% during the forecast period

Urokinase Market Size(US$)

CAGR 2025-2031

5.2%

Market Size,2031

USD 70.6

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 52.1 million

Market Forecast in 2031(Value)

US$ 70.6 million

CAGR

5.2%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Urokinase market is projected to grow from US$ 49.8 million in 2024 to US$ 70.6 million by 2031, at a CAGR of 5.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.

Global key players of urokinase include Syner-Med, LIVZON, Wanhua Biochem, etc. The top three players hold a share about 50%. China is the largest market of Urokinase, holding a share about 56%, followed by Europe and North America.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Urokinase market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Syner-Med
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems
LIVZON

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Urokinase Powder
Urokinase Solution

Segment by Application

Hospital
Clinic
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Urokinase study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.

Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.

Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.

Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.

Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.

Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.

Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.

Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles

Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.

Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.

Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 15: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:

Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Urokinase: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Urokinase Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Urokinase Powder

1.2.3 Urokinase Solution

1.3 Market Segmentation by Application

1.3.1 Global Urokinase Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Urokinase Revenue Estimates and Forecasts 2020-2031

2.2 Global Urokinase Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Urokinase Sales Estimates and Forecasts 2020-2031

2.4 Global Urokinase Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Urokinase Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Urokinase Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Urokinase Powder Market Size by Manufacturers

3.5.2 Urokinase Solution Market Size by Manufacturers

3.6 Global Urokinase Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Urokinase Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Urokinase Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Urokinase Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Urokinase Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Urokinase Sales and Revenue by Type (2020-2031)

6.4 North America Urokinase Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Urokinase Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Urokinase Sales and Revenue by Type (2020-2031)

7.4 Europe Urokinase Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Urokinase Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Urokinase Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Urokinase Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Urokinase Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Urokinase Sales and Revenue by Type (2020-2031)

9.4 Central and South America Urokinase Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Urokinase Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Urokinase Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Urokinase Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Urokinase Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Syner-Med

11.1.1 Syner-Med Corporation Information

11.1.2 Syner-Med Business Overview

11.1.3 Syner-Med Urokinase Product Models, Descriptions and Specifications

11.1.4 Syner-Med Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Syner-Med Urokinase Sales by Product in 2024

11.1.6 Syner-Med Urokinase Sales by Application in 2024

11.1.7 Syner-Med Urokinase Sales by Geographic Area in 2024

11.1.8 Syner-Med Urokinase SWOT Analysis

11.1.9 Syner-Med Recent Developments

11.2 Wanhua Biochem

11.2.1 Wanhua Biochem Corporation Information

11.2.2 Wanhua Biochem Business Overview

11.2.3 Wanhua Biochem Urokinase Product Models, Descriptions and Specifications

11.2.4 Wanhua Biochem Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Wanhua Biochem Urokinase Sales by Product in 2024

11.2.6 Wanhua Biochem Urokinase Sales by Application in 2024

11.2.7 Wanhua Biochem Urokinase Sales by Geographic Area in 2024

11.2.8 Wanhua Biochem Urokinase SWOT Analysis

11.2.9 Wanhua Biochem Recent Developments

11.3 Jiangxi Haoran Bio-Pharma

11.3.1 Jiangxi Haoran Bio-Pharma Corporation Information

11.3.2 Jiangxi Haoran Bio-Pharma Business Overview

11.3.3 Jiangxi Haoran Bio-Pharma Urokinase Product Models, Descriptions and Specifications

11.3.4 Jiangxi Haoran Bio-Pharma Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Jiangxi Haoran Bio-Pharma Urokinase Sales by Product in 2024

11.3.6 Jiangxi Haoran Bio-Pharma Urokinase Sales by Application in 2024

11.3.7 Jiangxi Haoran Bio-Pharma Urokinase Sales by Geographic Area in 2024

11.3.8 Jiangxi Haoran Bio-Pharma Urokinase SWOT Analysis

11.3.9 Jiangxi Haoran Bio-Pharma Recent Developments

11.4 Jiangsu Aidea Pharmaceutical

11.4.1 Jiangsu Aidea Pharmaceutical Corporation Information

11.4.2 Jiangsu Aidea Pharmaceutical Business Overview

11.4.3 Jiangsu Aidea Pharmaceutical Urokinase Product Models, Descriptions and Specifications

11.4.4 Jiangsu Aidea Pharmaceutical Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Jiangsu Aidea Pharmaceutical Urokinase Sales by Product in 2024

11.4.6 Jiangsu Aidea Pharmaceutical Urokinase Sales by Application in 2024

11.4.7 Jiangsu Aidea Pharmaceutical Urokinase Sales by Geographic Area in 2024

11.4.8 Jiangsu Aidea Pharmaceutical Urokinase SWOT Analysis

11.4.9 Jiangsu Aidea Pharmaceutical Recent Developments

11.5 Techpool

11.5.1 Techpool Corporation Information

11.5.2 Techpool Business Overview

11.5.3 Techpool Urokinase Product Models, Descriptions and Specifications

11.5.4 Techpool Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Techpool Urokinase Sales by Product in 2024

11.5.6 Techpool Urokinase Sales by Application in 2024

11.5.7 Techpool Urokinase Sales by Geographic Area in 2024

11.5.8 Techpool Urokinase SWOT Analysis

11.5.9 Techpool Recent Developments

11.6 Microbic Biosystems

11.6.1 Microbic Biosystems Corporation Information

11.6.2 Microbic Biosystems Business Overview

11.6.3 Microbic Biosystems Urokinase Product Models, Descriptions and Specifications

11.6.4 Microbic Biosystems Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Microbic Biosystems Recent Developments

11.7 LIVZON

11.7.1 LIVZON Corporation Information

11.7.2 LIVZON Business Overview

11.7.3 LIVZON Urokinase Product Models, Descriptions and Specifications

11.7.4 LIVZON Urokinase Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 LIVZON Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Urokinase Industry Chain

12.2 Urokinase Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Urokinase Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Urokinase Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Urokinase Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Urokinase Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Urokinase Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Urokinase Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Urokinase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Urokinase Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Urokinase Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Urokinase Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (BIU)

Table 7. Global Urokinase Sales by Region (2020-2025) & (BIU)

Table 8. Global Urokinase Sales by Region (2026-2031) & (BIU)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Urokinase Sales by Manufacturers (2020-2025) & (BIU)

Table 11. Global Urokinase Sales Share by Manufacturers (2020-2025)

Table 12. Global Urokinase Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Urokinase Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Urokinase by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urokinase as of 2024)

Table 16. Global Urokinase Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Urokinase Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/MIU)

Table 18. Key Manufacturers Urokinase Manufacturing Base and Headquarters

Table 19. Global Urokinase Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Urokinase Sales by Type (2020-2025) & (BIU)

Table 23. Global Urokinase Sales by Type (2026-2031) & (BIU)

Table 24. Global Urokinase Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Urokinase Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Urokinase ASP by Type (2020-2031) & (US$/MIU)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Urokinase Sales by Application (2020-2025) & (BIU)

Table 29. Global Urokinase Sales by Application (2026-2031) & (BIU)

Table 30. Urokinase High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Urokinase Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Urokinase Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Urokinase ASP by Application (2020-2031) & (US$/MIU)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Urokinase Growth Accelerators and Market Barriers

Table 37. North America Urokinase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Urokinase Sales (BIU) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Urokinase Growth Accelerators and Market Barriers

Table 40. Europe Urokinase Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Urokinase Sales (BIU) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Urokinase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Urokinase Sales (BIU) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Urokinase Growth Accelerators and Market Barriers

Table 45. Southeast Asia Urokinase Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Urokinase Investment Opportunities and Key Challenges

Table 47. Central and South America Urokinase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Urokinase Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Urokinase Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Syner-Med Corporation Information

Table 51. Syner-Med Description and Major Businesses

Table 52. Syner-Med Product Models, Descriptions and Specifications

Table 53. Syner-Med Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 54. Syner-Med Sales Value Proportion by Product in 2024

Table 55. Syner-Med Sales Value Proportion by Application in 2024

Table 56. Syner-Med Sales Value Proportion by Geographic Area in 2024

Table 57. Syner-Med Urokinase SWOT Analysis

Table 58. Syner-Med Recent Developments

Table 59. Wanhua Biochem Corporation Information

Table 60. Wanhua Biochem Description and Major Businesses

Table 61. Wanhua Biochem Product Models, Descriptions and Specifications

Table 62. Wanhua Biochem Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 63. Wanhua Biochem Sales Value Proportion by Product in 2024

Table 64. Wanhua Biochem Sales Value Proportion by Application in 2024

Table 65. Wanhua Biochem Sales Value Proportion by Geographic Area in 2024

Table 66. Wanhua Biochem Urokinase SWOT Analysis

Table 67. Wanhua Biochem Recent Developments

Table 68. Jiangxi Haoran Bio-Pharma Corporation Information

Table 69. Jiangxi Haoran Bio-Pharma Description and Major Businesses

Table 70. Jiangxi Haoran Bio-Pharma Product Models, Descriptions and Specifications

Table 71. Jiangxi Haoran Bio-Pharma Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 72. Jiangxi Haoran Bio-Pharma Sales Value Proportion by Product in 2024

Table 73. Jiangxi Haoran Bio-Pharma Sales Value Proportion by Application in 2024

Table 74. Jiangxi Haoran Bio-Pharma Sales Value Proportion by Geographic Area in 2024

Table 75. Jiangxi Haoran Bio-Pharma Urokinase SWOT Analysis

Table 76. Jiangxi Haoran Bio-Pharma Recent Developments

Table 77. Jiangsu Aidea Pharmaceutical Corporation Information

Table 78. Jiangsu Aidea Pharmaceutical Description and Major Businesses

Table 79. Jiangsu Aidea Pharmaceutical Product Models, Descriptions and Specifications

Table 80. Jiangsu Aidea Pharmaceutical Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 81. Jiangsu Aidea Pharmaceutical Sales Value Proportion by Product in 2024

Table 82. Jiangsu Aidea Pharmaceutical Sales Value Proportion by Application in 2024

Table 83. Jiangsu Aidea Pharmaceutical Sales Value Proportion by Geographic Area in 2024

Table 84. Jiangsu Aidea Pharmaceutical Urokinase SWOT Analysis

Table 85. Jiangsu Aidea Pharmaceutical Recent Developments

Table 86. Techpool Corporation Information

Table 87. Techpool Description and Major Businesses

Table 88. Techpool Product Models, Descriptions and Specifications

Table 89. Techpool Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 90. Techpool Sales Value Proportion by Product in 2024

Table 91. Techpool Sales Value Proportion by Application in 2024

Table 92. Techpool Sales Value Proportion by Geographic Area in 2024

Table 93. Techpool Urokinase SWOT Analysis

Table 94. Techpool Recent Developments

Table 95. Microbic Biosystems Corporation Information

Table 96. Microbic Biosystems Description and Major Businesses

Table 97. Microbic Biosystems Product Models, Descriptions and Specifications

Table 98. Microbic Biosystems Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 99. Microbic Biosystems Recent Developments

Table 100. LIVZON Corporation Information

Table 101. LIVZON Description and Major Businesses

Table 102. LIVZON Product Models, Descriptions and Specifications

Table 103. LIVZON Sales (BIU), Revenue (US$ Million), Price (US$/MIU) and Gross Margin (2020-2025)

Table 104. LIVZON Recent Developments

Table 105. Key Raw Materials Distribution

Table 106. Raw Materials Key Suppliers

Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 108. Milestones in Production Technology Evolution

Table 109. Distributors List

Table 110. Market Trends and Market Evolution

Table 111. Market Drivers and Opportunities

Table 112. Market Challenges, Risks, and Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

List of Figures

Figure 1. Urokinase Product Picture

Figure 2. Global Urokinase Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Urokinase Powder Product Picture

Figure 4. Urokinase Solution Product Picture

Figure 5. Global Urokinase Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Hospital

Figure 7. Clinic

Figure 8. Others

Figure 9. Urokinase Report Years Considered

Figure 10. Global Urokinase Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Urokinase Revenue (2020-2031) & (US$ Million)

Figure 12. Global Urokinase Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Urokinase Revenue Market Share by Region (2020-2031)

Figure 14. Global Urokinase Sales (2020-2031) & (BIU)

Figure 15. Global Urokinase Sales (CAGR) by Region (2020-2031) (BIU)

Figure 16. Global Urokinase Sales Market Share by Region (2020-2031)

Figure 17. Top 5 and Top 10 Manufacturers Urokinase Sales Volume Market Share in 2024

Figure 18. Global Urokinase Revenue Market Share Ranking (2024)

Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 20. Urokinase Powder Revenue Market Share by Manufacturer in 2024

Figure 21. Urokinase Solution Revenue Market Share by Manufacturer in 2024

Figure 22. Global Urokinase Sales Market Share by Type (2020-2031)

Figure 23. Global Urokinase Revenue Market Share by Type (2020-2031)

Figure 24. Global Urokinase Sales Market Share by Application (2020-2031)

Figure 25. Global Urokinase Revenue Market Share by Application (2020-2031)

Figure 26. North America Urokinase Sales YoY (2020-2031) & (BIU)

Figure 27. North America Urokinase Revenue YoY (2020-2031) & (US$ Million)

Figure 28. North America Top 5 Manufacturers Urokinase Sales Revenue (US$ Million) in 2024

Figure 29. North America Urokinase Sales Volume (BIU) by Type (2020- 2031)

Figure 30. North America Urokinase Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 31. North America Urokinase Sales Volume (BIU) by Application (2020-2031)

Figure 32. North America Urokinase Sales Revenue (US$ Million) by Application (2020-2031)

Figure 33. US Urokinase Revenue (2020-2031) & (US$ Million)

Figure 34. Canada Urokinase Revenue (2020-2031) & (US$ Million)

Figure 35. Mexico Urokinase Revenue (2020-2031) & (US$ Million)

Figure 36. Europe Urokinase Sales YoY (2020-2031) & (BIU)

Figure 37. Europe Urokinase Revenue YoY (2020-2031) & (US$ Million)

Figure 38. Europe Top 5 Manufacturers Urokinase Sales Revenue (US$ Million) in 2024

Figure 39. Europe Urokinase Sales Volume (BIU) by Type (2020-2031)

Figure 40. Europe Urokinase Sales Revenue (US$ Million) by Type (2020-2031)

Figure 41. Europe Urokinase Sales Volume (BIU) by Application (2020-2031)

Figure 42. Europe Urokinase Sales Revenue (US$ Million) by Application (2020-2031)

Figure 43. Germany Urokinase Revenue (2020-2031) & (US$ Million)

Figure 44. France Urokinase Revenue (2020-2031) & (US$ Million)

Figure 45. U.K. Urokinase Revenue (2020-2031) & (US$ Million)

Figure 46. Italy Urokinase Revenue (2020-2031) & (US$ Million)

Figure 47. Russia Urokinase Revenue (2020-2031) & (US$ Million)

Figure 48. Asia-Pacific Urokinase Sales YoY (2020-2031) & (BIU)

Figure 49. Asia-Pacific Urokinase Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Top 8 Manufacturers Urokinase Sales Revenue (US$ Million) in 2024

Figure 51. Asia-Pacific Urokinase Sales Volume (BIU) by Type (2020- 2031)

Figure 52. Asia-Pacific Urokinase Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 53. Asia-Pacific Urokinase Sales Volume (BIU) by Application (2020-2031)

Figure 54. Asia-Pacific Urokinase Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Indonesia Urokinase Revenue (2020-2031) & (US$ Million)

Figure 56. Japan Urokinase Revenue (2020-2031) & (US$ Million)

Figure 57. South Korea Urokinase Revenue (2020-2031) & (US$ Million)

Figure 58. China Taiwan Urokinase Revenue (2020-2031) & (US$ Million)

Figure 59. India Urokinase Revenue (2020-2031) & (US$ Million)

Figure 60. Central and South America Urokinase Sales YoY (2020-2031) & (BIU)

Figure 61. Central and South America Urokinase Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Central and South America Top 5 Manufacturers Urokinase Sales Revenue (US$ Million) in 2024

Figure 63. Central and South America Urokinase Sales Volume (BIU) by Type (2021-2031)

Figure 64. Central and South America Urokinase Sales Revenue (US$ Million) by Type (2020-2031)

Figure 65. Central and South America Urokinase Sales Volume (BIU) by Application (2020-2031)

Figure 66. Central and South America Urokinase Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Brazil Urokinase Revenue (2020-2025) & (US$ Million)

Figure 68. Argentina Urokinase Revenue (2020-2025) & (US$ Million)

Figure 69. Middle East, and Africa Urokinase Sales YoY (2020-2031) & (BIU)

Figure 70. Middle East and Africa Urokinase Revenue YoY (2020-2031) & (US$ Million)

Figure 71. Middle East and Africa Top 5 Manufacturers Urokinase Sales Revenue (US$ Million) in 2024

Figure 72. Middle East and Africa Urokinase Sales Volume (BIU) by Type (2021-2031)

Figure 73. South America Urokinase Sales Revenue (US$ Million) by Type (2020-2031)

Figure 74. Middle East and Africa Urokinase Sales Volume (BIU) by Application (2020-2031)

Figure 75. Middle East and Africa Urokinase Sales Revenue (US$ Million) by Application (2020-2031)

Figure 76. GCC Countries Urokinase Revenue (2020-2025) & (US$ Million)

Figure 77. Turkey Urokinase Revenue (2020-2025) & (US$ Million)

Figure 78. Egypt Urokinase Revenue (2020-2025) & (US$ Million)

Figure 79. South Africa Urokinase Revenue (2020-2025) & (US$ Million)

Figure 80. Urokinase Industry Chain Mapping

Figure 81. Regional Urokinase Manufacturing Base Distribution (%)

Figure 82. Global Urokinase Production Market Share by Region (2020-2031)

Figure 83. Urokinase Production Process

Figure 84. Regional Urokinase Production Cost Structure

Figure 85. Channels of Distribution (Direct Vs Distribution)

Figure 86. Bottom-up and Top-down Approaches for This Report

Figure 87. Data Triangulation

Figure 88. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 5.2% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What was the global market size of Urokinase in 2031? shouQi

What is the annual compound growth rate of the global Urokinase market size from 2025 to 2031? shouQi

What was the global market size of Urokinase in 2025? shouQi

Which companies rank high in the global Urokinase market? shouQi

Related Reports

Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Urokinase market size was US$ 82.09 million in 2025 and is forecast to reach a readjusted size of US$ 120 million by 2032 with a CAGR of 5.2% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 77
USD 4250.00
(Single User License)
Global Urokinase Market Research Report 2026
The global Urokinase market was valued at US$ 82.09 million in 2025 and is anticipated to reach US$ 120 million by 2032, at a CAGR of 5.2% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 116
USD 2900.00
(Single User License)
Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Urokinase was estimated to be worth US$ 82.09 million in 2025 and is projected to reach US$ 120 million, growing at a CAGR of 5.2% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 110
USD 3950.00
(Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Urokinase was estimated to be worth US$ 49.8 million and is forecast to reach approximately US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 121
USD 5900.00
(Single User License)
Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Urokinase market size was US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 79
USD 4250.00
(Single User License)
Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Urokinase was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Urokinase Market Research Report 2025
The global market for Urokinase was valued at US$ 49.8 million in the year 2024 and is projected to reach a revised size of US$ 70.6 million by 2031, growing at a CAGR of 5.2% during the forecast period.
Published Date: 2025-01-16
Pages: 79
USD 2900.00
(Single User License)
Global Urokinase Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published Date: 2024-04-17
Pages: 142
USD 5600.00
(Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published Date: 2024-04-16
Pages: 137
USD 5900.00
(Single User License)
Global Urokinase Market Insights, Forecast to 2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published Date: 2024-04-07
Pages: 89
USD 4900.00
(Single User License)

Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Urokinase market size was US$ 82.09 million in 2025 and is forecast to reach a readjusted size of US$ 120 million by 2032 with a CAGR of 5.2% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 77
USD 4250.00 (Single User License)
Global Urokinase Market Research Report 2026
The global Urokinase market was valued at US$ 82.09 million in 2025 and is anticipated to reach US$ 120 million by 2032, at a CAGR of 5.2% from 2026 to 2032.
Published: 2026-01-04
Pages: 116
USD 2900.00 (Single User License)
Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Urokinase was estimated to be worth US$ 82.09 million in 2025 and is projected to reach US$ 120 million, growing at a CAGR of 5.2% from 2026 to 2032.
Published: 2026-01-04
Pages: 110
USD 3950.00 (Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Urokinase was estimated to be worth US$ 49.8 million and is forecast to reach approximately US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 121
USD 5900.00 (Single User License)
Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Urokinase market size was US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 79
USD 4250.00 (Single User License)
Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Urokinase was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)
Global Urokinase Market Research Report 2025
The global market for Urokinase was valued at US$ 49.8 million in the year 2024 and is projected to reach a revised size of US$ 70.6 million by 2031, growing at a CAGR of 5.2% during the forecast period.
Published: 2025-01-16
Pages: 79
USD 2900.00 (Single User License)
Global Urokinase Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published: 2024-04-17
Pages: 142
USD 5600.00 (Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published: 2024-04-16
Pages: 137
USD 5900.00 (Single User License)
Global Urokinase Market Insights, Forecast to 2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published: 2024-04-07
Pages: 89
USD 4900.00 (Single User License)